Key facts
- It has raised $1.6M; the latest was Seed Round ($1.6M) in Jul 2025.
- Notable investors include E Squared, OneBio.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Altera Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Altera Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Altera Biosciences
Operator of a precision oncology diagnostics company intended to provide comprehensive genomic profiling to guide cancer treatment and monitor disease progression. The company offers advanced tumor profiling services that identify both common and rare cancer biomarkers from a single sample, enabling customers to make informed therapy decisions, track treatment response and detect recurrence early.
- Sector
- Healthcare
- HQ
- Tshwane, South Africa
- Founded
- 2024
- Website
- altera-bio.com/
- Ownership
- Privately Held (backing)
Altera Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Altera Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Altera Biosciences in its N-PORT filings yet. We sweep new filings monthly.